Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females

Infectious Agents and Cancer

Thomas W Weiss³  Silvia de Sanjose¹  Sharon Welner²  Harshila Patel²  Liga Bennetts²  Monika Wagner² 

[1] CIBER en Epidemiología y Salud Pública, Barcelona, Spain;LASER Analytica, Montréal, Québec, Canada;Merck Center for Observational and Real-World Evidence, West Point, PA, USA

关键词: Cervical cancer;    Cervical lesions;    Genital infection;    Epidemiology;    Geographic region;    Genotype;    HPV;   

Others  :  1211873
DOI  :  10.1186/s13027-015-0008-y

 received in 2015-01-29, accepted in 2015-04-15,  发布年份 2015

【 摘 要 】

Background

Country-level HPV genotyping data may be sought by decision-makers to gauge the genotype-specific burden of HPV-related diseases in their jurisdiction and assess the potential impact of HPV vaccines. We investigated, by country, the availability of published literature on HPV genotypes in cervical, vaginal and vulvar cancers and intraepithelial neoplasms (CINs, VaINs and VINs) and on prevalence and incidence of genital HPV infections among women without clinically manifest disease.

Findings

Primary sources of publications were the PubMed/Medline and EMBASE databases. Original studies or meta-analyses published from 2000, covering genotypes 16 and 18 and at least one of genotypes 31/33/45/52/58, were included. Key exclusion criteria were language not English, cervical lesions not histologically confirmed (cytology only), special populations (e.g., immunocompromised) and, for cervical studies, small population (<50). A total of 727 studies reporting HPV genotype-specific data were identified: 366 for cervical cancers and CINs, 43 for vulvar or vaginal cancers and VINs/VaINs, and 395 and 21 for infection prevalence and incidence, respectively, in general female population samples. A large proportion of studies originated from a small set of countries. Cervical cancer/CIN typing data was scarce for several regions with the highest cervical cancer burden, including Eastern, Middle and Western Africa, Central America, South-East Asia, South Asia, and Eastern Europe. Data for vulvar/vaginal disease was limited outside of Europe and North America.

Conclusions

Although a large body of published HPV genotype-specific data is currently available, data gaps exist for genotype-specific infection incidence and several world regions with the highest cervical cancer burden.

【 授权许可】

   
2015 Wagner et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-8.
• [2]Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-99.
• [3]Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G: A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013, 445(1–2):224-31.
• [4]Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Albero G, Cosano R, et al. Human papillomavirus and related diseases in the world. Summary report 2014-08-22.2014 Aug 22. http://www.hpvcentre.net/summaryreport.php.
• [5]de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-56.
• [6]de Sanjose S, Alemany L, Ordi J, Tous S, Alejo M: Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49(16):3450-61.
• [7]De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124(7):1626-36.
• [8]Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM: Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009, 113(4):917-24.
• [9]United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings.2013 Oct 31. http://unstats.un.org/unsd/methods/m49/m49regin.htm.
• [10]Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA: Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1777-84.
• [11]De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al.: The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013, 31(Suppl 5):F32-46.
• [12]Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al.: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7(1):38. BioMed Central Full Text
• [13]Serrano B, Alemany L, Ruiz PA, Tous S, Lima MA, Bruni L, et al.: Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiol 2014, 38:748-56.
• [14]Malloy C, Sherris J, Herdman C. HPV DNA testing: technical and programmatic issues for cervical cancer prevention in low-resource settings. PATH 2000 Dec. http://screening.iarc.fr/doc/HPV-DNA-Testing-Issues.pdf. Accessed 2014 Nov 21.
• [15]van der Zee RP, Richel O, De Vries HJ, Prins JM: The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 2013, 71(8):401-11.